Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (2.685)

1

Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors

enthalten in: International immunopharmacology | 2024

von Ma, J. | Song, J. | Yi, X. | +5

2

A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2024

von Wang, F. | Yu, X. | Qian, J. | +9

3

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer : study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

enthalten in: Trials | 2024

von Belotte, J. | Felicetti, B. | Baines, A. | +7

4

Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Du, P. | Long, Y. | Wang, M. | +7

5

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

enthalten in: Trials | 2024

von Belotte, J. | Felicetti, B. | Baines, A. | +7

6

Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors : A retrospective cohort study

enthalten in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2024

von Zhao, Y. | Yuan, H. | Chen, Y. | +4

7

Inactivation of VRK1 sensitizes ovarian cancer to PARP inhibition through regulating DNA-PK stability

enthalten in: Experimental cell research | 2024

von Kim, D. | Yun, H. | You, J. | +5

8

What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?

enthalten in: Immunotherapy | 2024

von de Mello, R. | Perez, K. | Haris, P.

9

"Having cancer is very expensive" : A qualitative study of patients with ovarian cancer and PARP inhibitor treatment

enthalten in: Gynecologic oncology | 2024

von Smith, A. | O'Brien, C. | Haggerty, A. | +2

10

NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors

enthalten in: Cell genomics | 2024

von Wang, Y. | Liu, X. | Zuo, X. | +24

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[269]